Formulation & Ingredients
Verified as at 23 September 2026
The short answer
GLP-1 companion product development should start with a specific nutritional use case. Define the intended consumer, evaluate evidence relevant to that use and test whether the serving is practical. Evidence for an ingredient in another population does not automatically establish a benefit in GLP-1 users or support a Canadian product claim.
Who this article is for
Supplement and functional-food brands developing products intended for adults using prescription GLP-1 therapies. This guide addresses product development, not individual treatment.
Key takeaways
Define one clear nutritional use case.
Distinguish direct evidence from extrapolation.
Test the real serving and review claims before finalizing the formula.
Build a useful nutrition product around a defined consumer need, a workable serving and a defensible claim.
What problem should a companion product solve?
The joint professional advisory on GLP-1 nutrition emphasizes adequate dietary intake, attention to gastrointestinal tolerability and support for muscle and bone health through diet and physical activity. It does not turn every ingredient associated with these goals into a proven GLP-1 companion supplement.
Translate the intended need into a development question. Is the product meant to provide protein in a convenient format, help meet fibre intake or address a defined nutritional gap? Each purpose leads to different formulation choices. A product designed to do everything may become too large, too expensive or unpleasant to use.
How should you evaluate ingredient evidence?
Build an evidence matrix before selecting the final blend. Record the study population, ingredient form, dose, duration, comparator, endpoint and limitations. Then state how closely the proposed commercial product matches. Do not treat a mechanistic explanation or supplier brochure as equivalent to a suitable clinical study.
For each benefit, write down what remains unknown. A positive study in exercising adults, for example, may help generate a research question without resolving performance in people using a prescription weight-management therapy. Keep those differences visible to both R&D and marketing.
Candidate | Development question | Evidence boundary to investigate |
Protein | Can the serving deliver the intended amount with acceptable volume and taste? | Nutritional role versus a product-specific muscle-preservation claim. |
Creatine | Is the format, daily amount and use case suitable? | Evidence in the proposed population and conditions of use. |
HMB | Does the exact ingredient and dose match relevant research? | Direct GLP-1 evidence versus extrapolation from other populations. |
Fibre | Can it be incorporated without unacceptable viscosity or sensory effects? | Fibre-specific outcomes, use directions and tolerability. |
Vitamins and minerals | What identified gap is the product intended to address? | Need, total exposure and the suitability of each proposed level. |
Protein drinks, powders or capsules: which format fits?
Choose the format after establishing the amount of material the concept needs. Protein-focused concepts require a different serving strategy from low-mass ingredients. Calculate the finished serving, including flavour, sweeteners, acids, stabilizers and processing aids, rather than judging feasibility from the actives alone.
For a powder, evaluate mixing in the intended water volume and after realistic standing time. For a ready-to-drink product, consider process compatibility, sedimentation and package stability. For a bar, assess texture during storage and the practical portion size. These are development questions to test, not assumptions that can be settled by a supplier specification.
Why sweetness, viscosity and serving burden matter
Prototype a small number of deliberate alternatives rather than repeatedly adding masking ingredients to a weak base. Record the mixing procedure, temperature, holding time and observations for every sample so useful comparisons survive beyond the tasting session.
Build a tolerability review into the brief with appropriate clinical input for the intended audience. Adding several fibres, minerals and other functional ingredients together can make it harder to identify what drives an unpleasant experience. Feedback from a tasting panel is helpful for sensory design but is not clinical evidence of safety or efficacy in GLP-1 users.
What can a Canadian GLP-1 companion product claim?
For an NHP, claims, packaging and advertising must align with the terms of market authorization. A food product needs a separate food-claim assessment. Calling a product a “companion” does not remove the need to assess its complete message.
Proposed positioning | Question before using it |
Protein or nutrient support | Does the product meet the applicable conditions for the exact statement? |
Prevents muscle loss during GLP-1 treatment | Is there adequate evidence and an appropriate authorization for this specific claim? |
Treats medication-related nausea or constipation | Does this imply a treatment claim beyond the intended product pathway? |
Works like a prescription GLP-1 medicine | Does the overall message misleadingly imply drug equivalence? |
A sensible development sequence
First, write a one-page brief naming the consumer, nutritional purpose, proposed claim, format and cost target. Second, review the evidence and likely regulatory pathway before purchasing an extensive ingredient set. Third, develop and compare prototypes against predefined criteria.
After choosing a candidate, specify the material grades and manufacturing process, assess appropriate safety and compatibility questions, and plan the relevant testing. Finalize the label only after the formula and claim strategy agree. For a novel population-specific benefit, discuss what additional research would be required rather than silently extrapolating from unrelated studies.
What to prepare
Target consumer and the specific nutritional need you intend to address
Proposed claims and launch markets
Ingredient shortlist with supplier, form and proposed daily amount
Target serving size, flavour, texture and price
Relevant studies, including the population and formulation tested
Manufacturing format, pack size and testing expectations
Frequently asked
Does every GLP-1 user need a supplement?
No universal product need should be assumed. Individual nutrition and treatment decisions belong with the person’s healthcare team. A commercial brief should define the use case and intended audience.
Can protein alone be marketed as preventing muscle loss?
That specific claim requires its own evidence and regulatory assessment. The advisory discusses nutrition alongside physical activity; it is not proof for a finished supplement claim.
Should we combine protein, creatine, HMB and fibre?
Only if each has a justified role and the complete serving is workable. Compare simpler prototypes before committing to a large blend.
Can we put GLP-1 in the product name?
Assess the name together with the label, imagery and advertising. A name can contribute to the overall claim and should not imply an unsupported therapeutic relationship.
Can Kompete help with both the formula and claims?
Yes. The project can connect ingredient and format selection with evidence review and Canadian pathway planning, with specialist input scoped where needed.
Where we can help
Next step
General guidance only goes so far. Send us the formula, the label, the request or the market, and we will tell you what we would do next.
Discuss a GLP-1 companion formula

